What Influences Patient Outcome in Obstructive Airway Disease?

This study has been completed.
Sponsor:
Information provided by:
University of Dundee
ClinicalTrials.gov Identifier:
NCT01221480
First received: October 14, 2010
Last updated: October 19, 2010
Last verified: October 2010
  Purpose

The aim of this observational study is to utilise the established record linkage data available in Tayside to investigate hospital admissions, exacerbations and mortality in COPD.


Condition
COPD

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Beta-Blockers Reduce Mortality and Exacerbations When Added to Stepwise Inhaled Therapy for COPD Without Adverse Effects on Lung Function.

Further study details as provided by University of Dundee:

Primary Outcome Measures:
  • All-cause Mortality

Secondary Outcome Measures:
  • Hospital Admissions
  • COPD exacerbations

Enrollment: 5977
Study Start Date: August 2010
Estimated Study Completion Date: October 2010
Groups/Cohorts
Beta Blocker Use
No beta blocker use

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

COPD patients within NHS Tayside, UK

Criteria

Inclusion Criteria:

  • Data collected through TARDIS database

Exclusion Criteria:

  • History of asthma or malignancy. Less than 50 years of age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Dr Philip M Short, University of Dundee
ClinicalTrials.gov Identifier: NCT01221480     History of Changes
Other Study ID Numbers: SHO002
Study First Received: October 14, 2010
Last Updated: October 19, 2010
Health Authority: United Kingdom: Tayside Medical Research Ethics Committee

Additional relevant MeSH terms:
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 24, 2014